Table 1 Ascorbic Acid Cancer Trials
From: Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?
Condition | Number of Patients | Dose/Route | Finding | Ref |
|---|---|---|---|---|
Mixture of solid tumors at different stages | 49 | Intravenous for 10 days 10 g and subsequently daily oral 10 g/day | 17 pts no response, 10 pts minimal response, 11 pts growth retardation, 2 pts cytostasis, 5 pts tumor regression, 4 pts tumor hemorrhage/necrosis | 11 |
Terminal cancer patients | 39 | Intravenous 10 g vitamin C twice with a 3-day interval and an oral intake of 4 g vitamin C daily for a week | Health score improved from 36+/-18 to 55+/-16 (p = 0.001). Significantly higher scores for physical, role, emotional, and cognitive function (p < 0.05). In symptom scale, the patients reported significantly lower scores for fatigue, nausea/vomiting, pain, and appetite loss (p < 0.005). | 12 |
Terminal cancer patients | 100 cancer pts treated as compared to 1000 controls. 50 of the treated pts were in the publication described in ref 11. | Intravenous for 10 days 10 g and subsequently daily oral 10 g/day | Mean survival time > 4.2 times as great for the ascorbate subjects (more than 210 days) as for the controls (50 days). Survival-time curves indicate that deaths occur for about 90% of the ascorbate-treated patients at one-third the rate for the controls and that the other 10% have a much greater survival time, averaging more than 20 times that for the controls. | 13 |
Terminal cancer patients | 99 in one hospital and 31 in another hospital | 30g/day intravenously | Hospital #1: Survival of 43 days for 44 low-ascorbate patients and 246 days for 55 high-ascorbate patients. Hospital #2: 48 days for 19 control patients and 115 days for 6 high-ascorbate patients. | 15 |
Terminal cancer patients | 60 AA, 63 placebo controlled | 10 g/day oral | The two groups showed no appreciable difference in changes in symptoms, performance status, appetite or weight. The median survival for all patients was about seven weeks, and the survival curves essentially overlapped. | 16 |
Advanced colorectal cancer | 50 AA, 50 control | 10 g/day oral | AA treatment had advantage over placebo with regard to either the interval between the beginning of treatment and disease progression or patient survival. Among patients with measurable disease, none had objective improvement. | 17 |
Renal metastatic, B cell lymphoma, Bladder cancer | 3 Cases | 50-100 g intravenously, various regimens | Tumor regression and unexpectedly long survival. | 201 |